难治性慢性淋巴细胞白血病通过脾脏放射栓塞成功桥接至 CAR-T 细胞治疗
Refractory Chronic Lymphocytic Leukemia Successfully Bridged to CAR T-Cell Therapy Using Splenic Radioembolization.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
DISEASE HUB
FOR TREATMENT
登记显示招募中的试验排在最前,共 1 项。同一状态内中国中心优先;具体中心是否开放须核实。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Refractory Chronic Lymphocytic Leukemia Successfully Bridged to CAR T-Cell Therapy Using Splenic Radioembolization.
Targeting the Epigenetic-Immune Axis in Acute Myeloid Leukemia: Current Advances and Future Directions.
近期研究已鉴定出多种可成药的表观遗传调控因子,包括 DNA 甲基转移酶、TET 双加氧酶、组蛋白甲基转移酶和去甲基化酶,以及组蛋白乙酰转移酶和去乙酰化酶。这些发现推动了低甲基化药物、突变型 IDH1/2 抑制剂、menin-MLL 和 DOT1L 拮抗剂、EZH2 和 LSD1 抑制剂以及类别特异性 HDAC 抑制剂的开发,其中数种已获批或正在进行晚期临床评价。
Non-Malignant T Cells as Determinants of Immunotherapeutic Response in Chronic Lymphocytic Leukemia: Towards Personalized Strategies.
High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model.
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.
Mapping the Global Clinical Trial Landscape of Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Pe
MEMBER ACCOUNT
登录成功会直接打开下一页。